Skip to main content Back to Top
Advertisement

5/26/2020

Dexrazoxane Injection

Products Affected - Description

    • Zinecard injection, Pfizer, 500 mg, vial, 1 count, NDC 00013-8727-89
    • Dexrazoxane injection, Hikma, 250 mg, vial, 1 count, NDC 00143-9247-01

Reason for the Shortage

    • Cumberland Pharmaceuticals relaunched Totect in late-July 2017.
    • Fosun Pharma has dexrazoxane available.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has dexrazoxane available.
    • Pfizer states manufacturing delay as the reason for the shortage.

Available Products

    • Totect kit, Cumberland Pharmaceuticals, 500 mg, vial, (only for extravasation injuries) 1 count, NDC 66220-0110-01
    • Zinecard injection, Pfizer, 250 mg, vial, 1 count, NDC 00013-8717-62
    • Dexrazoxane injection, Fosun Pharma, 500 mg, vial, 1 count, NDC 72266-0101-01
    • Dexrazoxane injection, Hikma, 500 mg, vial, 1 count, NDC 00143-9248-01
    • Dexrazoxane injection, Mylan Institutional, 250 mg, vial, 1 count, NDC 67457-0207-25
    • Dexrazoxane injection, Mylan Institutional, 500 mg, vial, 1 count, NDC 67457-0208-50

Estimated Resupply Dates

    • Hikma has dexrazoxane 250 mg vials on back order and the company estimates a release date of early-June 2020.
    • Pfizer has Zinecard 500 mg vials on back order and the company estimates a release date of August 2020.

Updated

Updated May 26, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 30, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.